This filing is purely administrative, no change in buyback pace or strategy. Monitor future filings for any modification to the program or material corporate events. For a $200B market cap company, weekly buyback disclosures of this magnitude are not price-relevant.
NVO drugs
NVO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 9 $44.56entry
- T+1 · 2mo ago −1.23%α −0.63% · $44.01
- T+5 · 2mo ago −6.40%α −5.74% · $41.71
- T+20 · 6w ago −14.14%α −16.08% · $38.26
- T+48 · todayOpen
- T+60 · in 16d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novo Nordisk filed a routine 6-K reporting weekly share repurchase activity under its existing DKK 15 billion buyback program. The company repurchased ~1.06M B shares for ~DKK 314.1M during the week of August 31–September 4, 2026, at an average price of ~DKK 297.5 per share. This is a standard periodic disclosure with no new material information, the buyback was announced months ago and is proceeding as planned.
Key Facts
- Novo Nordisk repurchased 1,055,000 B shares during August 31–September 4, 2026, for a total transaction value of approximately DKK 314.1 million.
- Accumulated repurchases under the program initiated May 6, 2026: 17,275,000 B shares for approximately DKK 5.22 billion.
- Total repurchases since the broader 12-month program began February 4, 2026: 32,034,179 B shares for approximately DKK 9.02 billion, at an average price of DKK 281.63 per share.
- Novo Nordisk now holds 46,074,876 B shares as treasury shares, representing 1.0% of total share capital of 4,465,000,000 A and B shares.
- The overall program authorizes up to DKK 15 billion in repurchases over 12 months from February 4, 2026.
Financial Impact
Routine buyback execution, approximately DKK 314.1M in repurchases for the week. No new authorization or change in program size.
Risk Factors
- None, this is a routine disclosure of ongoing share repurchases with no new authorization or change in terms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005925 |
| Document: 0001171843-26-005925-index-headers.html | 0001171843-26-005925 |
| Document: 0001171843-26-005925-index.html | 0001171843-26-005925 |
| Document: 0001171843-26-005925.txt | 0001171843-26-005925 |
Track record
43 reports on NVO
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 Now $41.60 −0.69% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 3/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 1/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 9, 20267d ago 6-K Neutral 2/10 Entry $41.38 Now $41.60 +0.53% settles Dec 8
- Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 Now $41.60 −1.38% settles Dec 3
- Nov 3, 202613d ago 6-K Neutral 2/10 Entry $40.19 Now $41.60 +3.51% settles Dec 2
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 Now $41.60 +6.31% settles Nov 23
- Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 Now $41.60 +7.58% settles Nov 24
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers